Many employers and insurers are scaling back coverage and Medicare doesn’t cover the drugs for obesity. Meantime, some big ...

The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...

Supplies of high-demand obesity drugs are improving – but they’re not easier to get - ‘There are a lot of people right now ...

While Ozempic is covered by most health plans, weight loss drugs such as Wegovy are not currently covered by Medicare and other insurance. Don't expect a 20% S&P 500 three-peat this year ...

Ozempic/Wegovy is the first drug on HHS's 2025 list of Medicare price negotiations. As the leaders of the pharmaceutical industry boarded their planes to come home from the JP Morgan Healthcare ...

Novo Nordisk’s obesity therapy Wegovy has cut the risk of death by ... “It is likely that insurers, and Medicare, will revise their coverage on the basis of the trial to cover the drug for ...

But unprecedented demand has made it difficult for the companies to manufacture sufficient supplies, even though Medicare and some ... about its version of Wegovy was omitted.

The Food and Drug Administration said on Friday that there is no longer a shortage of drugs like Wegovy and Ozempic. The semaglutide known as Ozempic is intended to be used for people with diabetes.